Fighting viruses is as easy as breathing
The Pharma Data
APRIL 8, 2022
Based on these studies, one of those drugs was licensed to Cantex Pharmaceuticals for the treatment of COVID-19 and other inflammatory lung diseases. Data from the research were recently included in the company’s Investigational New Drug (IND) application to the FDA to initiate a Phase 2 clinical trial for COVID-19.
52 
Let's personalize your content